1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Autor: | F. Saad, A.J. Armstrong, A. Thiery-Vuillemin, M. Oya, N.D. Shore, G. Procopio, C. Arslan, N. Mehra, F. Parnis, E. Brown, F. Constans Schlurmann, J.Y. Joung, M. Sugimoto, O. Sartor, Y-Z. Liu, C.H. Poehlein, C. Desai, P.M.D. Del Rosario, N. Clarke |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Annals of Oncology. 33:S1160 |
ISSN: | 0923-7534 |
Databáze: | OpenAIRE |
Externí odkaz: |